# STIMULUS-MDS2 (NCT04266301)

> Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04266301
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Novartis Pharmaceuticals
- Conditions: Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic
- Interventions: Sabatolimab; Azacitidine; Placebo
- Enrollment: 530
- Primary outcome: Overall Survival (OS) (Primary Efficacy Results)
- Primary outcome: Overall Survival (OS) (Final Efficacy Results)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 11
- Podcasts: 3
- YouTube: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=stimulus-mds2-nct04266301

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04266301", "email": "<work email>"}; the inbox owner confirms by the emailed link.